ACHV / Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript

Efficacy: Phase 3 ORCA-3 trial showed significant efficacy of cytisinicline in smoking cessation, reinforcing data from ORCA-2. Safety: Cytisinicline more_horizontal

Achieve Life Sciences Inc. ACHV, +12.88% said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine de more_horizontal

SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmace more_horizontal

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Nicole Jones - Investor Rel more_horizontal

ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase more_horizontal

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Nicole Jones - Investor more_horizontal

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Bencich - CEO & Director more_horizontal

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug more_horizontal